Aceglutamide (INN, JAN) (brand name Neuramina), or aceglutamide aluminum (JAN, USAN) (brand name Glumal), also known as acetylglutamine, is a psychostimulant, nootropic, and antiulcer agent that is marketed in Spain and Japan. Aceglutamide functions as a prodrug to glutamine with improved potency and stability. Aceglutamide is used as a psychostimulant and nootropic, while aceglutamide aluminum is used in the treatment of ulcers. Aceglutamide can also be used as a liquid-stable source of glutamine to prevent damage from protein energy malnutrition.

Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland. Corticotropin acts through the stimulation of cell surface the adrenocorticotropic hormone (ACTH) receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Corticotropin is indicated as monotherapy for the treatment of exacerbations of multiple sclerosis in adults and infantile spasms in infants and children under 2 years of age. Controlled clinical trials have shown Corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. The mechanism of action of Corticotropin in the treatment of infantile spasms is unknown.

7TM Pharma was developing obinepitide, a subcutaneously administered dual neuropeptide Y (NPY) Y2 and Y4 receptors agonist, for the treatment of obesity. Obinepitide is a synthetic analogue of two natural human hormones, PYY and Pancreatic Polypeptide, which normally are released during a meal. These hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS. In obinepitide, the properties of both of these hormones have been implanted into a single molecule. Obinepitide targets the Y2 and Y4 receptors, with selectivity over the Y1 receptor, which is involved in causing cardiovascular side effects. Obinepitide inhibited food intake up to nine hours after dosing.